Makovsky Unit will Help Pharma Clients with Regulatory Issues
Charting the future of public relations
Holmes Report
CEO

Makovsky Unit will Help Pharma Clients with Regulatory Issues

The health sciences division at Makovsky & Company has introduced a new unit called MARC that will assist healthcare companies communicate their accreditation status and regulatory compliance.

Paul Holmes

NEW YORK—The health sciences division at New York public relations firm Makovsky & Company has introduced a new unit called MARC (Makovsky Accreditation & Regulatory Communications) that will assist healthcare companies communicate their accreditation status, regulatory compliance and positions on complex domestic and international regulatory issues. The firm says it expects the service to appeal to healthcare providers, life science, drug, diagnostic and device companies.
 
“We created MARC as a solution for our clients who need to communicate to both their internal and external audiences the ways in which they are effectively complying in today’s heavily regulated medical and scientific environment,” says Donna Ramer, managing director of Makovsky Health Sciences. “Communications about these issues will become increasingly more important as regulations about privacy and quality of life issues take their place along side legislative, safety and efficacy issues.”
 
Ramer says the unit grew out of the firm’s experience working with heavily regulated pharmaceutical products, including those approved under the U.S. Food & Drug Administration’s subpart H regulation. 
 
Kristie Coneys Kuhl, an assistant vice president who holds a juris doctor and is experienced in developing and implementing communications strategies that address regulatory thickets, will manage the division, reporting directly to Ramer. Amy Losak, vice president and director media relations, will drive media strategy and outreach for MARC clients.
View Style:

Load 3 More
comments powered by Disqus